Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. (Q37785947)

23 August 2017

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. (English)

1 reference

23 August 2017

phase III clinical trial

0 references

0 references

0 references

1 reference

Monica Vaccari

1

1 reference

PubMed ID

20822342

23 August 2017

Poonam Poonam

series ordinal

2

1 reference

PubMed ID

20822342

23 August 2017

Genoveffa Franchini

series ordinal

3

1 reference

23 August 2017

1 September 2010

1 reference

Expert Review of Vaccines

23 August 2017

1 reference

23 August 2017

9

1 reference

23 August 2017

9

1 reference

23 August 2017

997-1005

1 reference

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

23 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Support for the RV144 HIV vaccine trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

HIV vaccine research in Thailand: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

The spread of HIV-1 subtypes B and CRF01_AE among injecting drug users in Bangkok, Thailand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Acceptability of A-CASI by HIV-positive IDUs in a multisite, randomized, controlled trial of behavioral intervention (INSPIRE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Poxviruses as expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

The use of nonhuman primate models in HIV vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

HIV vaccines: the Uganda experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.104

Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.

21 January 2018

2 references

https://api.crossref.org/works/10.1586%2FERV.10.104

21 January 2018

12 December 2020

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene

1 reference

12 December 2020

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

1 reference

12 December 2020

Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand

1 reference

12 December 2020

Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1.

1 reference

12 December 2020

The prime-boost concept applied to HIV preventive vaccines

1 reference

12 December 2020

Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys

1 reference

12 December 2020

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1 reference

12 December 2020

A report of three cases of AIDS in Thailand.

1 reference

12 December 2020

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

1 reference

12 December 2020

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

1 reference

12 December 2020

Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity.

1 reference

12 December 2020

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

1 reference

12 December 2020

Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys

1 reference

12 December 2020

Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.

1 reference

12 December 2020

A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

1 reference

12 December 2020

Potential use of non-replicating vectors as recombinant vaccines

1 reference

12 December 2020

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand

1 reference

12 December 2020

Preventive HIV vaccine development in Thailand.

1 reference

12 December 2020

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope

1 reference

12 December 2020

Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system

1 reference

12 December 2020

Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected Adults

1 reference

12 December 2020

AIDSVAX is safe, but efficacy question remains. VaxGen founder discusses quest for AIDS vaccine.

1 reference

12 December 2020

The safety and use of canarypox vectored vaccines

1 reference

12 December 2020

Safe and effective poxvirus vectors--NYVAC and ALVAC

1 reference

12 December 2020

Form, function, and use of retroviral gag proteins

1 reference

12 December 2020

Identifiers

DOI

10.1586/ERV.10.104

1 reference

23 August 2017

0 references

1 reference

PubMed ID

20822342